Texas Permanent School Fund Corp Has $2.56 Million Holdings in Haemonetics Corporation $HAE

Texas Permanent School Fund Corp trimmed its holdings in Haemonetics Corporation (NYSE:HAE) by 17.9% in the 2nd quarter, Holdings Channel reports. The fund owned 34,307 shares of the medical instruments supplier’s stock after selling 7,467 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Haemonetics were worth $2,560,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of HAE. Invesco Ltd. boosted its holdings in Haemonetics by 10.1% in the 1st quarter. Invesco Ltd. now owns 105,645 shares of the medical instruments supplier’s stock valued at $6,714,000 after purchasing an additional 9,654 shares during the period. Nuveen LLC acquired a new position in shares of Haemonetics during the first quarter valued at about $10,340,000. Raymond James Financial Inc. lifted its stake in shares of Haemonetics by 60.6% in the first quarter. Raymond James Financial Inc. now owns 390,856 shares of the medical instruments supplier’s stock valued at $24,839,000 after buying an additional 147,492 shares during the period. AlphaQuest LLC grew its position in Haemonetics by 71.5% during the first quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier’s stock worth $200,000 after buying an additional 1,309 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Haemonetics by 448.0% during the first quarter. MetLife Investment Management LLC now owns 316,542 shares of the medical instruments supplier’s stock valued at $20,116,000 after acquiring an additional 258,776 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 0.4%

Shares of HAE stock opened at $80.21 on Friday. The company has a market capitalization of $3.75 billion, a P/E ratio of 23.45, a P/E/G ratio of 1.51 and a beta of 0.30. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $68.43 and a 200 day moving average price of $64.84.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.Haemonetics’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on HAE. Weiss Ratings reiterated a “hold (c-)” rating on shares of Haemonetics in a research report on Monday, December 8th. Raymond James Financial reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. Robert W. Baird lifted their price target on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, November 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.10.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.